open access

Vol 88, No 6 (2020)
Research paper
Published online: 2020-11-01
Submitted: 2020-06-27
Accepted: 2020-07-29
Get Citation

Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience

Ram Niwas, Aneesa Shahul S, M K Garg, Vijaya lakshmi Nag, Pradeep Kumar Bhatia, Naveen Dutt, Nishant Chauhan, Jaykaran Charan, Shahir Asfahan, Praveen Sharma, Pankaj Bhardwaj, Mithu Banerjee, Pawan Garg, Binit Sureka, Gopal Krishna Bohra, Maya Gopalakrishnan, Sanjeev Misra
DOI: 10.5603/ARM.a2020.0139
·
Pubmed: 33393643
·
Adv Respir Med 2020;88(6):515-519.

open access

Vol 88, No 6 (2020)
ORIGINAL PAPERS
Published online: 2020-11-01
Submitted: 2020-06-27
Accepted: 2020-07-29

Abstract

Introduction: Chloroquine and its analogues are currently being investigated for the treatment and post exposure prophylaxis of COVID-19 due to its antiviral activity and immunomodulatory activity.
Material and methods: Confirmed symptomatic cases of COVID-19 were included in the study. Patients were supposed to receive chloroquine (CQ) 500 mg twice daily for 7 days. Due to a change in institutional protocol, initial patients received chloroquine and subsequent patients who did not receive chloroquine served as negative controls. Clinical effectiveness was determined in terms of timing of symptom resolution and conversion rate of reverse transcriptase polymerase chain reaction (RT-PCR) on day 14 and day 15 of admission.
Results: Twelve COVID-19 patients formed the treatment arm and 17 patients were included in the control arm. The duration of symptoms among the CQ treated group (6.3 ± 2.7 days) was significantly (p-value = 0.009) lower than that of the control group (8.9 ± 2.2 days). There was no significant difference in the rate of RT-PCR negativity in both groups. 2 patients out of 12 developed diarrhea in the CQ therapy arm.  
Conclusion: The duration of symptoms among the treated group (with chloroquine) was significantly lower than that of the control group. RT-PCR conversion was not significantly different between the 2 groups.

Abstract

Introduction: Chloroquine and its analogues are currently being investigated for the treatment and post exposure prophylaxis of COVID-19 due to its antiviral activity and immunomodulatory activity.
Material and methods: Confirmed symptomatic cases of COVID-19 were included in the study. Patients were supposed to receive chloroquine (CQ) 500 mg twice daily for 7 days. Due to a change in institutional protocol, initial patients received chloroquine and subsequent patients who did not receive chloroquine served as negative controls. Clinical effectiveness was determined in terms of timing of symptom resolution and conversion rate of reverse transcriptase polymerase chain reaction (RT-PCR) on day 14 and day 15 of admission.
Results: Twelve COVID-19 patients formed the treatment arm and 17 patients were included in the control arm. The duration of symptoms among the CQ treated group (6.3 ± 2.7 days) was significantly (p-value = 0.009) lower than that of the control group (8.9 ± 2.2 days). There was no significant difference in the rate of RT-PCR negativity in both groups. 2 patients out of 12 developed diarrhea in the CQ therapy arm.  
Conclusion: The duration of symptoms among the treated group (with chloroquine) was significantly lower than that of the control group. RT-PCR conversion was not significantly different between the 2 groups.

Get Citation

Keywords

COVID-19; chloroquine; viral conversion; safety profile

About this article
Title

Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients — initial experience

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 6 (2020)

Article type

Research paper

Pages

515-519

Published online

2020-11-01

DOI

10.5603/ARM.a2020.0139

Pubmed

33393643

Bibliographic record

Adv Respir Med 2020;88(6):515-519.

Keywords

COVID-19
chloroquine
viral conversion
safety profile

Authors

Ram Niwas
Aneesa Shahul S
M K Garg
Vijaya lakshmi Nag
Pradeep Kumar Bhatia
Naveen Dutt
Nishant Chauhan
Jaykaran Charan
Shahir Asfahan
Praveen Sharma
Pankaj Bhardwaj
Mithu Banerjee
Pawan Garg
Binit Sureka
Gopal Krishna Bohra
Maya Gopalakrishnan
Sanjeev Misra

References (16)
  1. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224): 565–574.
  2. WHO. Coronavirus disease (COVID-2019) situation reports. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. [Last accessed 28.03.2020].
  3. Wahba L, Jain N, Fire AZ, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798): 265–269.
  4. Zhu Na, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733.
  5. Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020; 92(6): 595–601.
  6. Guan WJ, Ni ZY, Hu Yu, et al. Clinical characteristics of coronavirus disease 2019 in china. N Engl J Med. 2020; 382(18): 1708–1720.
  7. Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses — drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15(5): 327–347.
  8. Zhonghua Jie He He Hu Xi Za Zhi. Multicenter Collaboration Group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumoniaExpert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia [in Chinese], 43 (2020).
  9. Gao J, Tian Z, Yang Xu. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14(1): 72–73.
  10. Savarino A, Trani LDi, Donatelli I, et al. New insights into the antiviral effects of chloroquine. The Lancet Infectious Diseases. 2006; 6(2): 67–69.
  11. Chinese Clinical Trial Registry. Available at: www.chictr.org.cn/ searchproj.aspx?title=%E6%B0%AF%E5%96%B9&offi cialname=&subjectid=&secondaryid=&applier=&study leader=ðicalcommitteesanction=&sponsor=&studya ilment=&studyailmentcode=&studytype=0&studystage= 0&studydesign=0&minstudyexecutetime=&maxstudyexe cutetime=&recruitmentstatus=0&gender=0&agreetosign =&secsponsor=®no=®status=0&country=&prov ince=&city=&institution=&institutionlevel=&measure= &intercode=&sourceofspends=&createyear=0&isupload rf=&whetherpublic=&btngo=btn&verifycode=&page=1. [Last accessed: 09.03.2020]. .
  12. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018; 9(2).
  13. Liu Y, Zhang C, Huang F, et al. 2019–novel coronavirus (2019-nCoV) infections trigger an exaggerated cytokine response aggravating lung injury. Available at: http://chinaxiv.org/abs/202002.00018. [Last accessed: 01.04.2020].
  14. Rosendaal FR, Gautret P, Lagier JC, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1): 105949.
  15. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369: m1849.
  16. van den Broek MPH, Möhlmann JE, Abeln BGS, et al. Chloroquine-induced QTc prolongation in COVID-19 patients. Neth Heart J. 2020; 28(7-8): 406–409.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl